MENLO PARK, Calif.--(BUSINESS WIRE)--Spinal Modulation, a privately held international medical device company, completed enrollment of the ACCURATE study, a randomized, controlled pivotal clinical trial designed to evaluate the safety and efficacy of the company’s Axium® Neurostimulator System. The Axium System is a targeted form of spinal cord stimulation (SCS), which uses an implantable medical device to deliver mild electrical pulses that mask or interrupt pain signals as they travel from the periphery to the brain. Unlike traditional SCS devices, the Axium System uniquely targets the dorsal root ganglion (DRG), a neural structure within the spine that has been shown to play a critical role in the development and maintenance of chronic pain1.
Help employers find you! Check out all the jobs and post your resume.
